Psychopharmacology

, Volume 65, Issue 3, pp 265–272 | Cite as

Platelet monoamine oxidase activity in first-degree relatives of schizophrenic patients

  • Peter Propping
  • Waltraut Friedl
Original Investigations

Abstract

Platelet monoamine oxidase (MAO) is under genetic control. A lower MAO activity in chronic schizophrenia has repeatedly been reported, and it has been suggested that reduced activity of this enzyme reflects an increased vulnerability to schizophrenia. To test this hypothesis platelet MAO was determined in 65 first-degree relatives of 22 schizophrenic index patients and in matched healthy controls. No difference in mean activity between the two samples could be detected, suggesting that reduced MAO activity in schizophrenia is more likely to be a phenomenon secondary to the disease. A significant parent-offspring correlation of MAO activities was obtained.

Key words

Monoamine oxidase Schizophrenia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baenziger, N. L., Majerus, P. W.: Isolation of human platelets and platelet surface membranes. In: Methods in enzymology, vol. XXXI, part A. S. Fleischer, L. Packer, eds., pp. 149–155. New York, San Francisco, London: Academic 1974Google Scholar
  2. Becker, R. E., Shaskan, E. G.: Platelet monoamine oxidase activity in shizophrenic patients. Amer. J. Psychiat. 134, 512–517 (1977)Google Scholar
  3. Belmaker, R. H., Ebbesen, K., Ebstein, R., Rimon, R.: Platelet monoamine oxidase in schizophrenia and manic-depressive illness. Brit. J. Psychiat. 129, 227–232 (1976)Google Scholar
  4. Benson, P. F., Southgate, J.: Diminished activity of platelet monoamine oxidase in Down's syndrome. Amer. J. Hum. Genet. 23, 211–214 (1971)Google Scholar
  5. Berger, P. A., Ginsburg, R. A., Barchas, J. D., Murphy, D. L., Wyatt, R. J.: Platelet monoamine oxidase in chronic schizophrenic patients. Amer. J. Psychiat. 135, 95–99 (1978)Google Scholar
  6. Berrettini, W. H., Vogel, W. H., Clouse, R.: Platelet monoamine oxidase in chronic schizophrenia. Amer. J. Psychiat. 134, 805–806 (1977)Google Scholar
  7. Berrettini, W. H., Prozialeck, W., Vogel, W. H.: Decreased platelet monoamine oxidase activity in chronic schizophrenia, shown with novel substrates. Arch. Gen. Psychiat. 35, 600–605 (1978)Google Scholar
  8. Buchsbaum, M. S., Coursey, R. D., Murphy, D. L.: The biochemical high-risk paradigm: Behavioral and familial correlates of low platelet monoamine oxidase activity. Science 194, 339–341 (1976)Google Scholar
  9. Buchsbaum, M. S., Murphy, D. L., Coursey, R. D., Lake, C. R., Ziegler, M. S.: Platelet monoamine oxidase, plasma dopamine-beta-hydroxylase and attention in a ‘biochemical high-risk’ sample. In: The nature of schizophrenia. L. C. Wynne, ed., pp. 387–396. New York: John Wiley 1978Google Scholar
  10. Campbell, M., Friedman, E., Green, W. H., Small, A. M., Burdock, E. I.: Blood platelet monoamine oxidase activity in schizophrenic children and their families. A preliminary study. Neuropsychobiol. 2, 239–246 (1976)Google Scholar
  11. Carpenter, W. T., Murphy, D. L., Wyatt, R. J.: Platelet monoamine oxidase activity in acute schizophrenia. Amer. J. Psychiat. 132, 438–441 (1975)Google Scholar
  12. Demisch, L., v. d. Mühlen, H., Bochnik, H. J., Seiler, N.: Substratetypic changes of platelet monoamine oxidase activity in subtypes of schizophrenia. Arch. Psychiat. Nervenkr. 224, 319–329 (1977)Google Scholar
  13. Domino, E. F., Khanna, S. S.: Decreased blood platelet MAO activity in unmedicated chronic schizophrenic patients. Amer. J. Psychiat. 133, 323–326 (1976)Google Scholar
  14. Friedhoff, A. J., Miller, J. C., Weisenfreund, J.: Human platelet MAO in drug-free and medicated schizophrenic patients. Amer. J. Psychiat. 135, 952–955 (1978)Google Scholar
  15. Friedman, E., Shopsin, B., Sathananthan, G., Gershon, S.: Blood platelet monoamine oxidase in psychiatric patients. Amer. J. Psychiat. 131, 1392–1394 (1974)Google Scholar
  16. Leckman, J. F., Gershon, E. S., Nichols, A. S., Murphy, D. L.: Reduced MAO activity in first-degree relatives of individuals with bipolar affective disorders. Arch. Gen. Psychiat. 34, 601–606 (1977)Google Scholar
  17. Lienert, G. A.: Verteilungsfreie Methoden in der Biostatik. Meisenheim am Glan Hain 1973Google Scholar
  18. Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, R. J.: Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265–275 (1951)Google Scholar
  19. Major, L. F., Murphy, D. L.: Platelet and plasma amine oxidase activity in alcoholic individuals. Brit. J. Psychiat. 132, 548–554 (1978)Google Scholar
  20. Meltzer, H. Y., Stahl, S. M.: Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. Res. Comm. Chem. Pathol. Pharmacol. 7, 419–431 (1974)Google Scholar
  21. Murphy, D. L., Belmaker, R. H., Buchsbaum, M., Martin, N. F., Ciaranello, R., Wyatt, R. J.: Biogenic amine-related enzymes and personality variations in normals. Psychologic. Med. 7, 149–157 (1977a)Google Scholar
  22. Murphy, D. L., Belmaker, R., Carpenter, W. T., Wyatt, R. J.: Monoamine oxidase in chronic schizophrenia: Studies of hormonal and other factors affecting enzyme activity. Brit. J. Psychiat. 130, 151–158 (1977b)Google Scholar
  23. Murphy, D. L., Belmaker, R., Wyatt, R. J.: Monoamine oxidase in schizophrenia and other behavioral disorders. J. Psychiat. Res. 11, 221–247 (1974)Google Scholar
  24. Murphy, D. L., Donnelly, C. H., Miller, L., Wyatt, R. J.: Platelet monoamine oxidase in chronic schizophrenia: Some enzyme characteristics relevant to reduced activity. Arch. Gen. Psychiat. 33, 1377–1381 (1976a)Google Scholar
  25. Murphy, D. L., Weiss, R.: Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. Amer. J. Psychiat. 128, 1351–1357 (1972)Google Scholar
  26. Murphy, D. L., Wright, C., Buchsbaum, M., Nichols, A., Costa, J. L., Wyatt, R. J.: Platelet and plasma amine oxidase activity in 680 normals: Sex and age differences and stability over time. Biochem. Med. 16, 254–265 (1976b)Google Scholar
  27. Murphy, D. L., Wyatt, R. J.: Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature 238, 225–226 (1972)Google Scholar
  28. Nies, A., Robinson, D. S., Harris, L. S., Lamborn, K. R.: Comparison of monoamine oxidase substrate activities in twins, schizophrenics, depressives and controls. In: Neuropsychopharmacology of monoamines and their regulatory enzymes. E. Usdin, ed., pp. 59–70. New York: Raven 1974Google Scholar
  29. Owen, F., Bourne, R., Crow, T. J., Johnstone, E. C., Bailey, A. R., Hershon, H. I.: Platelet monoamine oxidase in schizophrenia: An investigation in drug-free chronic hospitalized patients. Arch. Gen. Psychiat. 33, 1370–1373 (1976)Google Scholar
  30. Owen, F., Ridges, P., Cookson, I. B.: Monoamine oxidase activity: A genetic marker of schizophrenia? Acta Genet. Med. Gemellol. (Roma) 23, 371–376 (1973)Google Scholar
  31. Schildkraut, J. J., Herzog, J. M., Orsulak, P. J., Edelman, S. E., Shein, H. M., Frazier, S. H.: Reduced platelet monoamine oxidase activity in a subgroup of schizophrenic patients. Amer. J. Psychiat. 133, 438–440 (1976)Google Scholar
  32. Schildkraut, J. J., Orsulak, P. J., Schatzberg, A. F., Cole, J. O., Gudeman, J. E., Rohde, W. A.: Elevated platelet MAO activity in schizophrenia-related depressive disorders. Amer. J. Psychiat. 135, 110–112 (1978)Google Scholar
  33. Sullivan, J. L., Cavenar, J. O., Stanfield, C. N., Hammett, E. B.: Reduced MAO activity in platelets and lymphocytes of chronic schizophrenics. Amer. J. Psychiat. 135, 597–598 (1978a)Google Scholar
  34. Sullivan, J. L., Stanfield, C. N., Dackis, C.: Platelet MAO activity in schizophrenia and other psychiatric illnesses. Amer. J. Psychiat. 134, 1098–1103 (1977)Google Scholar
  35. Sullivan, J. L., Stanfield, C. N., Maltbie, A. A., Hammett, E., Cavenar, J. O.: Stability of low platelet monoamine oxidase activity in human alcoholics. Biol. Psychiat. 13, 391–397 (1978b)Google Scholar
  36. Takahashi, S., Yamane, H., Naosuke, T.: Reduction of blood platelet monoamine oxidase in schizophrenic patients on phenothiazines. Folia Psychiat. Neurol. Jap 29, 207–214 (1975)Google Scholar
  37. Van Kammen, D. P., Marder, S. R., Murphy, D. L., Bunney, W. E.: MAO activity, CSF amine metabolites, and drug-free improvement in schizophrenia. Amer. J. Psychiat. 135, 567–569 (1978)Google Scholar
  38. White, H. L., McLeod, M. N., Davidson, J. R. T.: Platelet monoamine oxidase activity in schizophrenia. Amer. J. Psychiat. 133, 1191–1193 (1976)Google Scholar
  39. Winter, H., Herschel, M., Propping, P., Friedi, W., Vogel, F.: A twin study on three enzymes (DBH, COMT, MAO) of catecholamine metabolism. Correlations with MMPI. Psychopharmacology 57, 63–69 (1978)Google Scholar
  40. Wurtman, R. J., Axelrod, J.: Sex steroids, cardiac 3H-norepinephrine, and tissue monoamine oxidase levels in the rat. Biochem. Pharmacol. 12, 1417–1419 (1963)Google Scholar
  41. Wyatt, R. J., Murphy, D. L., Belmaker, R., Cohen, S., Donnelly, C. H., Pollin, W.: Reduced monoamine oxidase activity in platelets: A possible genetic marker for vulnerability to schizophrenia. Science 173, 916–918 (1973)Google Scholar
  42. Zeller, E. A., Boshes, B., Davis, J. M., Thorner, M.: Molecular aberration in platelet monoamine oxidase in schizophrenia. Lancet 1975I, 1385 (1975)Google Scholar

Copyright information

© Springer-Verlag 1979

Authors and Affiliations

  • Peter Propping
    • 1
    • 2
  • Waltraut Friedl
    • 1
    • 2
  1. 1.Institut für Humangenetik der Universität HeidelbergHeidelbergFederal Republic of Germany
  2. 2.Zentralinstitut für Seelische GesundheitMannheimFederal Republic of Germany

Personalised recommendations